These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27018162)

  • 1. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
    Richter J; Biran N; Duma N; Vesole DH; Siegel D
    Hematol Oncol; 2017 Jun; 35(2):246-251. PubMed ID: 27018162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
    Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
    Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
    Scott LJ
    Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
    San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
    Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
    Hagiwara M; Panjabi S; Sharma A; Delea TE
    J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
    [No Abstract]   [Full Text] [Related]  

  • 8. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
    Trudel S; Tessoulin B; Jullien M; Blin N; Gastinne T; Mahé B; Dubruille V; Bonnet A; Lok A; Chevallier P; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1441-1447. PubMed ID: 30874851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
    Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
    Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X
    Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.
    Park H; Byun JM; Yoon SS; Koh Y; Yoon SW; Shin DY; Hong J; Kim I
    PLoS One; 2022; 17(1):e0260113. PubMed ID: 35085238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
    Li Y; Kassir N; Wang X; Palmisano M; Zhou S
    J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
    Moreau P; Dimopoulos MA; Richardson PG; Siegel DS; Cavo M; Corradini P; Weisel K; Delforge M; O'Gorman P; Song K; Chen C; Bahlis N; Oriol A; Hansson M; Kaiser M; Anttila P; Raymakers R; Joao C; Cook G; Sternas L; Biyukov T; Slaughter A; Hong K; Herring J; Yu X; Zaki M; San-Miguel J
    Eur J Haematol; 2017 Sep; 99(3):199-206. PubMed ID: 28504846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
    Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
    J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
    Maciocia N; Melville A; Cheesman S; Sharpley F; Ramasamy K; Streetly M; Jenner M; Benjamin R; Schey S; Maciocia P; Popat R; D'sa S; Rismani A; Cerner A; Yong K; Rabin N
    Br J Haematol; 2017 Mar; 176(6):908-917. PubMed ID: 28211054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
    Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
    Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.